Connie Leanza
Acute Care · Tullahoma, TNNPI 1205921152
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 311 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,000, 4.8 times the $415 reported in 2021. Among acute care clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 311 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$799
- Boehringer Ingelheim$729
- Takeda Pharmaceuticals U.S.A., Inc.$472
- Sanofi$314
- Grifols USA, LLC$313
- plus $2K from 20 others
What the payments were for
- Food & beverage$5,924100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 68 | $1,353 |
| GSK | 54 | $799 |
| Boehringer Ingelheim | 35 | $729 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $472 |
| Sanofi | 16 | $314 |
| Grifols USA, LLC | 15 | $313 |
| Mylan Specialty L.p. | 15 | $260 |
| Harmony Biosciences LLC | 15 | $256 |
| Electromed, Inc. | 15 | $246 |
| Avadel CNS Pharmaceuticals, LLC | 7 | $174 |
| Baxter Healthcare | 7 | $160 |
| Verona Pharma, Inc. | 8 | $159 |
| Regeneron Healthcare Solutions, Inc. | 8 | $144 |
| Jazz Pharmaceuticals Inc. | 6 | $101 |
| Insmed, Inc. | 4 | $86 |
| Philips North America LLC | 4 | $71 |
| Inspire Medical Systems, Inc. | 2 | $48 |
| Actelion Pharmaceuticals US, Inc. | 2 | $47 |
| Axsome Therapeutics, Inc. | 2 | $45 |
| United Therapeutics Corporation | 2 | $35 |
| Advanced Respiratory, Inc | 1 | $31 |
| Lilly USA, LLC | 1 | $27 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Viatris Specialty LLC | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$107
How this compares
$5,935 in reported general payments places this provider in the 90th percentile of 738 acute care providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 391 | $331,974 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 302 | $219,744 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 16 | $179,424 |
| OfevNintedanib Esylate | 16 | $138,277 |
| Breo ElliptaFluticasone/Vilanterol | 100 | $56,162 |
| Dupixent PenDupilumab | 12 | $44,726 |
| Spiriva RespimatTiotropium Bromide | 29 | $26,975 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 34 | $11,866 |
| SymbicortBudesonide/Formoterol Fumarate | 35 | $11,166 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 438 | $10,622 |
| Advair HfaFluticasone Propion/Salmeterol | 20 | $10,185 |
| DuleraMometasone/Formoterol | 23 | $9,881 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $9,032 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $8,434 |
| Incruse ElliptaUmeclidinium Bromide | 18 | $7,069 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $799 | $404,236523 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,353 | $230,910337 claims |
| Grifols USA, LLCProlastin C | $313 | $179,42416 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $729 | $173,68662 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 738 acute care providers in Tennessee.
Other acute care in Tullahoma
- Jessica BonarTullahoma$10K
- Haley HoyNashville$368K
- Anne AlexandrovMemphis$110K
- Stephen MillerKnoxville$108K
- Shannon GraceNashville$57K
- Timothy BallardKnoxville$47K
- Kelsey MartinNashville$42K
- Barbara BrownNashville$36K
- Michelle GoochChattanooga$35K
- Elizabeth DavidsonNashville$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.